Saturday, March 15, 2025 5:08:07 PM
Yet, Delve Insight has DCVax as the #1 treatment for GBM through 2030. (https://www.delveinsight.com/report-store/dcvax-l-emerging-drug-insight-and-market-forecast). Go figure.
Your comment that other approvals will take excessive time seems off the mark. Pharmaceutical companies with approved drugs may receive conditional approvals and accelerated pathways for other indications and combination therapies. Additional confirmatory trials typically do not involve reinventing the wheel.
Lastly, I'm curious about your knowledge of NorthWest's financial relationships with "big pharma". I'm guessing you're guessing. Here's what I do know:
Despite all the negativity posted 24/7 on this board, Northwest has a very loyal longstanding shareholder base, that seems to understand the science and broad potential of the DCVax platform. I doubt that will decline with the MHRA's upcoming approval decision.
You guys have been very busy lately.
_________________________
Be prepared for another lost decade...The problem is they don’t have a big pharma partner who is willing to...
Your comment that other approvals will take excessive time seems off the mark. Pharmaceutical companies with approved drugs may receive conditional approvals and accelerated pathways for other indications and combination therapies. Additional confirmatory trials typically do not involve reinventing the wheel.
Lastly, I'm curious about your knowledge of NorthWest's financial relationships with "big pharma". I'm guessing you're guessing. Here's what I do know:
Despite all the negativity posted 24/7 on this board, Northwest has a very loyal longstanding shareholder base, that seems to understand the science and broad potential of the DCVax platform. I doubt that will decline with the MHRA's upcoming approval decision.
You guys have been very busy lately.
_________________________
Be prepared for another lost decade...The problem is they don’t have a big pharma partner who is willing to...
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
